Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder: An open label maintenance study

European Child and Adolescent Psychiatry

Volumn 17, Issue 4, 2008, Pages 217-225

  Gencer, Ozlem ^a   Emiroglu, F Neslihan Inal ^a   Miral, Suha ^a   Baykara, Burak ^a   Baykara, Aysen ^a   Dirik, Eray ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Autistic disorder; Haloperidol; Risperidone

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; ADULT; ARTICLE; AUTISM; BLUNT AFFECT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYMPTOMS RATING SCALE; FEMALE; HUMAN; INCREASED APPETITE; MAINTENANCE THERAPY; MALE; MOOD DISORDER; NOCTURNAL ENURESIS; OPEN STUDY; RATING SCALE; RITVO FREEMAN REAL LIFE RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; TURGAY DSM IV PERVASIVE DEVELOPMENTAL DISORDER RATING SCALE; UKU SIDE EFFECT RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; PROSPECTIVE STUDIES; RISPERIDONE; TIME; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 42549099634     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-007-0656-6     Document Type: Article

References (38)

1. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-489
2. Aman MG, Singh NN (1985) Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 89:492-502
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). American Psychiatric Association, Washington DC
4. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202
5. Anderson L, Campbell M Adams P, Small AM, Perry R, Shell J (1989) The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239
6. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E (2003) Parent defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42 (12):1443-1450
7. Campbell M, Schopler E, Cueva JE, Hallin A (1996) Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 35:134-143
8. Campbell M, Armentos JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843
9. Campbell M, Rapoport JL, Simpson GM (1999) Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:537-545
10. Casaer P, Croonenberghs JAN, Lagae L, Deboutte D (2002) Risperidone in the treatment of childhood autistic disorder: an open pilot study. Acta Neuropsychiatrica 14:242-249
11. Chouinard G, Ross- Chouinard A, Annable L (1980) Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233
12. Chouinard G, Annable L, Ross- Chouinard A (1982) Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. Am J Psychiatry 139 (3):312-318
13. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT (1980) Behavioral effects of haloperİdol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Adolesc Psychiatry 19:665-667
14. Findling RL, Maxwell K, Wiznitzer M (1997) An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33:155-159
15. Findling RL, McNamara NK (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65(Suppl 6):30-44
16. Freeman BJ, Ritvo ER, Yokota A, Ritvo A (1986) A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 25:130-136
17. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E (2004) Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39-47
18. Ganguli R (2000) Weight gain associated with antipsychotic drugs. J Clin Psychiatry 60(suppl 9):678
19. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education and Welfare, Rockville
20. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke L (1999) Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557-565
21. Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR (2003) Measurement of antipsychotic-induced side effects:support for the validity of a self report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacol Clin Exp 18:405-411
22. Lingjaerde O, Ahlfors UG, Bech P Dencker SJ Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 334(suppl):1-100
23. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147
24. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125-1127
25. Masi GM, Cosenza A, Mucci M, Brovedani P (2003) A 3-year naturalistic study of preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047
26. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med (5):314-321
27. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH Cohen DJ (1997) Risperidone treatment of children and adolescents with pervasive developmental disorder: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693
28. McDougle CJ, Holmes JP, Carlson DC, Pelton GGH, Cohen DJ, Price LH (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641
29. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM (2005) Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162:1142-1148
30. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-376
31. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE (1989) Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28:87-92
32. Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, Mason-Brothers A, August GJ, Klykylo W, Leventhal B, Lewis K, Piggott L, Realmuto G, Stubbs EG, Umansky R (1986) Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 22:133-140
33. Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B (2001) Methodological issues in designing a multisided trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11:377-388
34. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-e641
35. Taylor E (1994) Physical treatments. In: Rutter M, Taylor E, Hersov L (eds) Child and adolescent psychiatry, modern approaches, 3rd edn. Great Britain: Bath Press, pp 880-899
36. Turgay A (1993) Turgay pervasive developmental disorders scale. Copyright and publication: Integrative Therapy Institute, West Bloomfield
37. Volkmar FR, Klin A, Cohen DJ (1997) Diagnosis and classification of autism and related conditions. In: Volkmar FR, Cohen DJ (eds) Handbook of autism and pervasive developmental disorders. New York, Wiley pp 5-40
38. Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79-90